Every material Form 8-K Allarity Therapeutics, Inc. has filed with the SEC since October 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Allarity Therapeutics entered a Settlement and Release Agreement with Novartis Pharma AG on October 28, 2026, resolving a liability of $4.9 million plus interest tied to a license agreement that was terminated effective January 26, 2024. Novartis agreed to accept $1.0 million as full payment, and both parties will release claims once the payment is received. Separately, the company announced on October 30, 2026 its first revenue-generating contract under its CLIA-certified laboratory services strategy, but the filing does not disclose the contract's value.
Liability owed to Novartis: $4.9 million plus interest, arising under a license agreement between Novartis and Allarity Therapeutics Europe ApS, an affiliate
Settlement payment: $1.0 million, accepted by Novartis as full payment of the liability upon receipt
Mutual releases of claims take effect upon receipt of the payment, subject to claims relating to enforcement of the agreement
October 30, 2026 press release: first revenue-generating contract under the CLIA-certified laboratory services strategy; contract value not disclosed
Allarity Therapeutics terminated its Common Stock Purchase Agreement with Tumim Stone Capital LLC on October 28, 2026, which had allowed the company to sell up to $6.0 million of newly issued common stock to Tumim at its discretion. The company said it chose to end the agreement to pursue alternative financing arrangements, and it will not sell further shares to Tumim under it.
Agreement dated January 28, 2026, allowed sales of up to $6.0 million of newly issued common stock to Tumim.
Termination effective October 28, 2026; the company says no early termination penalty is payable.
Indemnification and certain expense obligations survive termination.
The company plans to pursue alternative financing arrangements; the filing does not name them.
Allarity Therapeutics announced an update on its Drug Response Predictor (DRP) technology, recently awarded patents and CLIA-certified in-house lab, which it says support stenoparib's clinical development and external partnership opportunities. The filing contains no financial results, guidance or financing figures, so the update is a development-stage business announcement rather than a measure of current performance.
Recently awarded patents and CLIA certification of the in-house lab allow Allarity to extend the test as a companion diagnostic and retain sole control of the clinical test
The stenoparib-DRP is a 414-gene expression signature; an exploratory analysis presented at AACR 2026 linked higher DRP scores to longer overall survival in a prior Phase 2 ovarian cancer cohort
Allarity states stenoparib remains its principal development focus, with external partnerships an additional opportunity
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Allarity Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →